

CNMV  
Edison, 4  
28006 Madrid

Barcelona (Spain), March 16, 2017

## RELEVANT FACT

Dear Sir,

In accordance with the Article 228 of Royal Legislative Decree 4/2015, dated 23 October, which enacts the consolidated text of the Securities Market Act, LABORATORIO REIG JOFRE SA ("Reig Jofre" or "the Company") submits hereafter press release on the involvement of Reig Jofre with emerging biotech companies and research centers to drive new developments.

Adolf Rousaud  
Secretary of the Board of Directors  
Laboratorio Reig Jofre SA

## Social commitment

### REIG JOFRE JOINS SHIP2B FOUNDATION TO ACCOMPANY EMERGING COMPANIES OF SOCIAL IMPACT

- Ship2B is a private foundation that aims to accelerate business projects of high social impact by making available to entrepreneurs a wide community of mentors, experts, entities and large companies.
- Reig Jofre is joining the advisory group for health-related projects offering mentoring, advice, experience and knowledge to the entrepreneurial teams.
- The incorporation to Ship2B is part of Reig Jofre's commitment to facilitate the development of new projects and companies in the field of health and innovation and to accelerate the time-to-market of their products and/or services.

**Barcelona, March 16, 2017.** The pharmaceutical company Reig Jofre has joined Tech4health innovation and entrepreneurship platform of the Ship2B Foundation as a co-founding partner. Tech4health is an innovation-, entrepreneurship- and social investment node, whose main mission is to solve some of the health problems and challenges of our society. The objective is to accelerate business projects of high social impact by following-up and accompanying them by means of a community of mentors, experts, entities and large companies that operate as development tractors.

Tech4health promotes projects focused on the improvement and customization of medical treatments, monitoring and follow-up of patients, diagnosis of diseases, promotion of healthy lifestyles and improvement of the standard of living of allergic and intolerant people.

Reig Jofre's participation in Ship2B is part of Reig Jofre's commitment to biotech startups and research centers, mainly national, to boost the development of their projects and time to market.



In this sense, Reig Jofre fosters agreements with companies and research centers to co-develop innovative products in the company's specialty areas: injectable products complex to stabilize and formulate, and antibiotics derived from penicillin; products in the therapeutic areas of dermatology, gynecology and ENT, as well as consumer healthcare products and nutraceuticals.

As an example of such agreements, Reig Jofre took in 2015 a 5% stake in Bionure, a biotechnology company based in Barcelona and California, focused on neurodegenerative processes, where Reig Jofre brings its product development expertise, quality and regulatory requirements for conducting pre-clinical studies and clinical phases for an innovative sterile injectable for the treatment of multiple sclerosis, which is at the doorstep of clinical phases.

In the last two years, Reig Jofre has invested 1.5 million euros in supporting the development of national biotechnological startups. The clear willingness of the company to complement the developments of its internal R&D teams, with open innovation projects with other companies and research centers, is marking and will continue to do so in future, Reig Jofre's strategy to new product proposals.

According to Ignasi Biosca, CEO of Reig Jofre and president of CataloniaBio, the association of companies in the field of life sciences and health in Catalonia, *"Biotech products continue to position themselves as drivers in the innovation projects. There are opportunities to innovate and collaborative projects are a great way to bring strengths together to reduce the arrival time of the product to the market."*

Get timely updates of Reig Jofre news by registering in the company's **subscription centre** on the corporate website: **[www.reigjofre.com](http://www.reigjofre.com)**

### **About Reig Jofre**

Founded in Barcelona in 1929, Reig Jofre is a multinational pharmaceutical company with activity structured around two major axes: the main one, own-product manufacture and marketing (RJF Pharma, 80% of total sales) and a complementary one, development and manufacture for third parties (RJF CDMO, 20% of total sales). In its main activity, the company focuses on developing specialised technological products (antibiotics and solutions for injection); specialised therapeutic products for the dermatology, gynaecology and respiratory fields; and dietary supplements and consumer healthcare. The company focuses its R+D activity on developing new indications and/or pharmaceutical forms using known active substances, generic medicines with a particular focus on beta-lactam antibiotics and solutions for injection, topical dermatological products, OTCs and dietary supplements, and in addition develops new innovative molecules in partnership with start-ups and research centres.



Reig Jofre has over 900 employees, 4 development centres and 3 production centres in Europe, direct sales in 6 European countries and over 130 business partners in 63 countries across the world. The company closed 2016 with a turnover of 161 million euros.

Reig Jofre is listed on the Spanish Stock Exchange under the ticker RJF. Reig Jofre is listed on the Spanish Stock Exchange under the ticker RJF. Share capital: 63,214,220 shares.

**For further information:**

---

**Investors and analysts**

Gloria Folch

Tel. (+34) 93 480 67 10 – ext. 1241

gloria.folch@reigjofre.com

**Media**

Inma Santa-Pau

Tel. (+34) 93 480 67 10 – ext. 1242

inma.santapau@reigjofre.com